Connecting Hope and
Medical Science
    

      
 

CCRP Clinical Trials

Click here for Physician Area

Only show trials for the disease site :

DiseaseSiteProtocolNumberStatusTitle
BrainRTOG-0925OPENNatural History of Postoperative Cognitive Function, Quality of Life and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma.
BrainN107C (CTSU/NCCTG)OPENA Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease.
BrainN0577 (CTSU/NCCTG)OPENPhase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma.
BreastB-31OPENA Randomized Trial Comparing the Safety and Efficiacy of Adriamycin and Cyclophosphamide followed by Taxol plus Herceptin (AC T) to that of Adriamycin and Cyclophosphamide followed by Taxol Plus Herceptin (ACT+H) in Node-Positive Breast Cancer Patients who have Tumors that Overexpress HER2.
BreastB-50-I NSABP DIT/BO27938/GBG 77 (NSABP DIT)OPENA Randomized, Multicenter, Open Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with Her2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.
BreastA011106 (CTSU/Alliance)OPENALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
Breast40903 (CTSU/CALGB)OPENPhase II Study of Neoadjuvant Letrozole for Post-Menopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS).
BreastB-51OPENA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.
BreastB-43OPENA Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
BreastB-52OPENA Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER-2 Posiutive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
1234567